Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tuma

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Journal of the National Cancer Institute|September 10, 2009
PARP inhibitors: will the new class of drugs match the hype?Rabiya S Tuma
Journal of the National Cancer Institute|September 21, 2006
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpointsRabiya S Tuma
Journal of the National Cancer Institute|July 30, 2009
Stimulus funds force hard look at comparative effectiveness researchRabiya S Tuma
Journal of the National Cancer Institute|February 14, 2012
Functional screens take on the cancer genomeRabiya S Tuma
Journal of the National Cancer Institute|October 6, 2011
Enthusiasm for antibody-drug conjugatesRabiya S Tuma
Journal of the National Cancer Institute|June 30, 2012
Cancer stem cell hypothesis and trastuzumab in HER2-negative tumorsRabiya S Tuma
Journal of the National Cancer Institute|July 20, 2006
Phase I antibody risks, trial safety examinedRabiya S Tuma
Journal of the National Cancer Institute|January 8, 2004
Checking out the neighborhood: researchers examine environment's effect on tumor growthRabiya S Tuma
Drug Discovery Today|December 24, 2003
Drug designers seek a structural solutionRabiya S Tuma
Journal of the National Cancer Institute|March 12, 2011
Measuring the importance of PSA velocityRabiya S Tuma
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Journal of the National Cancer Institute|September 10, 2009
PARP inhibitors: will the new class of drugs match the hype?Rabiya S Tuma
Journal of the National Cancer Institute|September 21, 2006
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpointsRabiya S Tuma
Journal of the National Cancer Institute|July 30, 2009
Stimulus funds force hard look at comparative effectiveness researchRabiya S Tuma
Journal of the National Cancer Institute|February 14, 2012
Functional screens take on the cancer genomeRabiya S Tuma
Journal of the National Cancer Institute|October 6, 2011
Enthusiasm for antibody-drug conjugatesRabiya S Tuma
Journal of the National Cancer Institute|June 30, 2012
Cancer stem cell hypothesis and trastuzumab in HER2-negative tumorsRabiya S Tuma
Journal of the National Cancer Institute|July 20, 2006
Phase I antibody risks, trial safety examinedRabiya S Tuma
Journal of the National Cancer Institute|January 8, 2004
Checking out the neighborhood: researchers examine environment's effect on tumor growthRabiya S Tuma
Drug Discovery Today|December 24, 2003
Drug designers seek a structural solutionRabiya S Tuma
Journal of the National Cancer Institute|March 12, 2011
Measuring the importance of PSA velocityRabiya S Tuma
Pageof 11